Following the completion of chemotherapy.

AstraZeneca announces encouraging outcomes from olaparib stage II research in serous ovarian cancer AstraZeneca announced today encouraging outcomes from a stage II study in individuals with platinum-sensitive relapsed serous ovarian malignancy who had received maintenance treatment with the investigational medication olaparib, following the completion of chemotherapy. The outcomes of this study have already been featured today within the official American Culture of Clinical Oncology 2011 annual achieving press cast cialis-soft.html . Related StoriesNew results reveal association between colorectal cancer tumor and melanoma medication treatmentCornell biomedical engineers develop 'super organic killer cells' to destroy cancers cells in lymph nodesMD Anderson research reveals why chemotherapy medications not effective for most pancreatic cancers patientsIn this stage II, randomised, double-blind, multicenter, placebo-controlled study, olaparib 400 mg twice daily considerably extended progression free of charge survival by RECIST.

About Bristol-Myers Squibb Bristol-Myers Squibb can be a worldwide biopharmaceutical company whose objective would be to discover, develop and deliver innovative medications that help individuals prevail over serious illnesses.. AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides $5 million grant for American Diabetes Association’s Pathway to avoid Diabetes AstraZeneca and Bristol-Myers Squibb Organization today announced that the businesses’ U.S. Diabetes Alliance offers a three-12 months grant to the American Diabetes Association’s Pathway to avoid Diabetes system.